GALT Historical PE Ratio Notes

— Galectin Therapeutics (ticker symbol GALT) is a biotech company focused on developing therapeutics that target galectin proteins, mainly galectin-3, which are believed to play a crucial role in the progression of fibrosis & cancer. Its lead candidate, belapectin, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) cirrhosis, a serious liver disease with no currently approved treatments. When reviewing GALT's historical price, earnings, & price-to-earnings (PE) ratio data, it's key to keep in mind that Galectin Therapeutics, like many small-cap biotech firms, has not historically posted consistent earnings—its business model is heavily research-driven, and revenues from approved products are often years away or uncertain. As a result, there may be periods with negative earnings, making the PE ratio either extremely high or undefined (when earnings are negative), and large price swings due to speculation on clinical trial outcomes or FDA-related milestones. Understanding this context is important as conventional PE analysis may be less informative for GALT than for companies with steady profits, so looking at PE ratio trends alongside major development milestones & financial statements will give a clearer investor perspective.

On this page we presented the Galectin Therapeutics Historical PE Ratio information for Galectin Therapeutics' stock. The average GALT historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average GALT historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this GALT historical PE result, against the recent PE: when this page was posted on 5/15/2026, the most recent closing price for GALT had been 2.17, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on GALT or any other given stock, valuation analysis for GALT can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Galectin Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for GALT. Thanks for visiting, and the next time you need to research GALT Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.